Here’s how we can make clinical trials more inclusive

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Since COVID-19 made its way to the United States, we have seen a stream of worrying news of the pandemic’s impact on cancer care in the U.S., including 9.4 million missed screenings1 for just about all forms of cancer. While screening rates rebounded in the fall of 20202, there’s a growing concern from oncologists that screenings haven’t returned to pre-pandemic levels for everyone. 

And the data are compelling. From September to December 2020, for example, fewer Black and Hispanic women2 had mammograms than in the three months prior to the pandemic. In addition, Black men were 25% less likely3 than their white counterparts to get a prostatectomy during the pandemic. 

There is significant concern among health equity advocates that the pandemic’s ripple effects on cancer care could be sustaining or even deepening widely recognized and reported health disparities for vulnerable communities, including Black, Latinx, and rural Americans.4 Warnings from experts of the pandemic’s impact on cancer disparities necessitate an even greater urgency to further reduce gaps in care.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen
Table of Contents

YOU MAY BE INTERESTED IN

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening. 
The ASCERTAIN-V phase I/II clinical trial, which evaluated the first all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive induction chemotherapy, demonstrated favorable response rates and survival with expected myelosuppressive effects.
Talvey (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with Darzalez Faspro (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72% and clinically meaningful reduction of up to 53% in the risk of death compared to the standard regimen of Darzalez Faspro, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma, according to the results of the investigational phase III MonumenTAL-3 study. 
Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase inhibitor, plus a two-year venetoclax and rituximab regimen versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001), according to the results of the phase III BRUIN CLL-322 trial. The study met its primary endpoint of independent review committee-assessed progression-free survival.
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login